Keyphrases
Activation Receptor
29%
After Surgery
20%
Anti-glioma
44%
Antigen-presenting Cells
10%
Author Names
10%
Autologous Tumors
9%
Biomarker Panel
6%
Cancer Panel
20%
Canine
8%
CD200
100%
Cell Motility
7%
Checkpoint Activation
14%
DAP10
40%
Differentially Expressed Genes
6%
Extracellular Vesicles
40%
Gene Expression
8%
Glioblastoma
48%
Glioblastoma multiforme
6%
Glioma
6%
Group 3 Medulloblastoma
20%
High Sensitivity
20%
High Specificity
20%
High-grade Glioma
21%
Immune Activation
20%
Immune Checkpoint
40%
Immune Checkpoint Inhibitors
20%
Immune Checkpoint Molecules
8%
Leptomeningeal Disease
7%
Leptomeningeal Metastasis
20%
Mammalian Target of Rapamycin (mTOR)
7%
Maria
20%
Median Survival
8%
Medulloblastoma
10%
Metastasis
10%
MRNA Expression
6%
MTOR Complex 2 (mTORC2)
20%
Orthodenticle Homeobox 2
20%
Pet Dogs
20%
Primary Astrocytes
8%
Protein Expression
8%
RNA Sequencing (RNA-seq)
6%
Signaling Pathway
60%
T Cells
8%
Temozolomide
8%
Tumor
20%
Tumor Grade
12%
Tumor Growth
20%
Tumor Lysate
23%
Tumor Marker
23%
Vaccination
20%
Biochemistry, Genetics and Molecular Biology
Antigen Presenting Cell
6%
CD200
80%
Cell Lysate
23%
Cell Motility
5%
Eicosanoid Receptor
14%
Gene Mutation
10%
IDH1
10%
Immune Checkpoints
60%
Mechanistic Target of Rapamycin
7%
Messenger RNA
5%
Methylation
10%
Orthodenticle Homeobox 2
20%
Pet Animal
20%
Promoter Region
20%
Protein P53
10%
RNA
10%
RNA Sequence
20%
Signal Transduction
60%
T Cell
10%
Tumor Marker
10%
Tumor Progression
20%
Tumor Volume
10%
Wild Type
10%
Immunology and Microbiology
Antigen-Presenting Cell
12%
CD200
80%
CD200 Antigen
10%
Cell Lysate
23%
Central Nervous System
11%
Gene Mutation
10%
Immune Tolerance
5%
Immunity
5%
Immunomodulating Drugs
5%
Immunosuppressive Drug
5%
Immunotherapy
47%
Methylation
10%
P53
10%
Pet Animal
20%
Promoter Region
20%
RNA Sequence
20%
Signal Transduction
20%
T Cell
12%
Tumor Volume
10%
Vaccination Policy
22%
Vaccine Efficacy
28%
Wild Type
10%
